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Background: Deﬁcits in emotional processing can be detected in the pre-manifest stage of Huntington's
disease and negative emotion recognition has been identiﬁed as a predictor of clinical diagnosis. The
underlying neuropathological correlates of such deﬁcits are typically established using correlative
structural MRI studies. This approach does not take into consideration the impact of disruption to the
complex interactions between multiple brain circuits on emotional processing. Therefore, exploration of
the neural substrates of emotional processing in pre-manifest HD using fMRI connectivity analysis may
be a useful way of evaluating the way brain regions interrelate in the period prior to diagnosis.
Methods: We investigated the impact of predicted time to disease onset on brain activation when par-
ticipants were exposed to pictures of faces with angry and neutral expressions, in 20 pre-manifest HD
gene carriers and 23 healthy controls. On the basis of the results of this initial study went on to look at
amygdala dependent cognitive performance in 79 Huntington's disease patients from a cross-section of
disease stages (pre-manifest to late disease) and 26 healthy controls, using a validated theory of mind
task: “the Reading the Mind in the Eyes Test” which has been previously been shown to be amygdala
dependent.
Results: Psychophysiological interaction analysis identiﬁed reduced connectivity between the left
amygdala and right fusiform facial area in pre-manifest HD gene carriers compared to controls when
viewing angry compared to neutral faces. Change in PPI connectivity scores correlated with predicted
time to disease onset (r¼0.45, po0.05). Furthermore, performance on the “Reading the Mind in the Eyes
Test” correlated negatively with proximity to disease onset and became progressively worse with each
stage of disease.
Conclusion: Abnormalities in the neural networks underlying social cognition and emotional processing
can be detected prior to clinical diagnosis in Huntington's disease. Connectivity between the amygdala
and other brain regions is impacted by the disease process in pre-manifest HD and may therefore be a
useful way of identifying participants who are approaching a clinical diagnosis. Furthermore, the
“Reading the Mind in the Eyes Test” is a surrogate measure of amygdala function that is clinically useful
across the entire cross-section of disease stages in HD.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Huntington's disease (HD) is an incurable, progressive, neuro-
degenerative disorder characterised clinically by a triad of motor,17
r Ltd. This is an open access articl
rain Repair, Forvie Site, Ro-
331174.
he work contained in thiscognitive and psychiatric problems (Bates et al., 2002) which is
caused by an expanded cytosine–adenine–guanine (CAG) repeat in
exon 1 of the huntingtin gene. Neuropathological changes can be
detected decades before clinical signs emerge (Aylward et al.,
2004; Paulsen, 2010) beginning in the striatum and progressing to
widespread brain atrophy (Vonsattel et al., 2008). Although HD is
diagnosed based on the presence of unequivocal motor abnorm-
alities, cognitive abnormalities can be detected in most gene car-
riers prior to this point.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ecutive function, emotional processing and memory (Ho et al.,
2003; Henley et al., 2012; Tabrizi et al., 2013; Holl et al., 2013;
Nicoll et al., 2014; Georgiou-Karistianis et al., 2013, 2014; Johnson
et al., 2007; Stout et al., 2011; Begeti et al., 2013). In the prodromal
phase the impairment is more subtle but abnormalities in psy-
chomotor processing speed, verbal ﬂuency and the recognition of
negative emotions are common (Tabrizi et al., 2013, 2012; Begeti
et al., 2013). The direct functional implications of these cognitive
changes are still unclear (Kirkwood et al., 2002; Duff et al., 2010;
Van Liew et al., 2013) but, reduced occupational performance and
difﬁculty managing ﬁnances can be seen in pre-manifest HD gene
carriers (pre-HD) who are approaching diagnosis (Beglinger et al.,
2010). Furthermore, changes in personality and difﬁculties with
social interaction are key features of early HD. One explanation for
these occupational and social problems is an emerging impair-
ment in emotional oversight e.g. accurately identifying, inter-
preting and responding to the emotions and intentions of others
all of which are necessary for maintaining interpersonal interac-
tions and socially appropriate behaviour.
Multiple studies have shown that HD patients are impaired on
emotion recognition tasks (Johnson et al., 2007; Sprengelmeyer
et al., 2006, 1996; Milders et al., 2003; Henley et al., 2008; Gray
et al., 1997; Hennenlotter et al., 2004; Montagne et al., 2006; Wang
et al., 2003; Hayes et al., 2007; Mitchell et al., 2005). A recent
systematic review of the literature demonstrated that anger re-
cognition is the most consistently reported impairment, closely
followed by disgust and fear recognition (Henley et al., 2012) in
manifest disease. While in PMGC's, selective impairments in dis-
gust recognition have been found (Sprengelmeyer et al., 2006;
Gray et al., 1997; Hennenlotter et al., 2004) and a relationship
between anger recognition and proximity to estimated time of
disease onset has been reported (Johnson et al., 2007). However,
some studies argue that there is a more generalised impairment
encompassing all negative emotions (Johnson et al., 2007), with
change in negative emotion recognition over a three year period
having positive predictive value for identifying PMGC's who
reached a clinical diagnosis during that time (Tabrizi et al., 2013).
As such, emotion recognition may be a useful marker of very early
disease related changes in HD.
The underlying neural substrates of emotion recognition deﬁ-
cits in HD have typically been established using correlative
structural MRI studies (Tabrizi et al., 2013; Johnson et al., 2007;
Henley et al., 2008; Kipps et al., 2007). Such studies have identiﬁed
correlations between tissue degeneration in the striatum asso-
ciated with impaired recognition of surprise, disgust, anger and
fear (Henley et al., 2008); between the cerebellum (Scharmuller
et al., 2013) and anger recognition and between the anterior insula
and disgust recognition in both manifest (Henley et al., 2008;
Hennenlotter et al., 2004; Kipps et al., 2007) and pre-manifest
patients (Hennenlotter et al., 2004). It has been argued however,
that disease-related behavioural changes in HD are more likely to
relate to disruption of the complex interactions between multiple
brain circuits rather than as a result of distinct regional tissue
degeneration (Paulsen, 2009) which cannot be measured on
structural MRI.
Functional MRI has been used to interrogate emotional pro-
cessing in PMGC's in a small number of studies which look at
changes in Bold Oxygen Level Dependent (BOLD) response in brain
regions during emotional processing. This approach can therefore
detect disease related changes earlier than the classic approach.
Dogan et al. (2013) asked PMGC's to complete an emotion re-
cognition task whilst undergoing fMRI and reported that negative
stimuli evoked decreased activation in the amygdala, hippo-
campus, striatum, insula, cingulate and prefrontal cortices, as well
as in sensorimotor, temporal and visual areas. Other studiesmeasure implicit emotion perception to reduce the confounding
effects of performance on BOLD response, by asking participants to
perform a distracter task such as a gender decision task. Hen-
nenlotter and colleagues (Hennenlotter et al., 2004) looked at
neural activation to grey scale pictures of faces displaying either
disgusted, surprised or neutral expressions in PMGC's. BOLD re-
sponse was reported to be lower than controls in the left dorsal
(intermediate) anterior insula/opercular region and left putamen
during disgust (relative to neutral) processing. However, Novak
and colleagues found activation differences in a widely distributed
network of brain regions involved including prefrontal, partietal
and cingulate cortices during disgust, anger and happiness pro-
cessing which was not restricted to any particular emotional ex-
pression or emotion valence (Novak et al., 2012).
ToM refers to an individual's ability to understand the presence
of beliefs, feelings, intentions and interests in other people that
can differ from their own and from reality (Baird and Astington,
2004). The ability to attribute mental states to others is likely to
have a central role on human social interaction as it allows us to
predict the behaviour of others. Furthermore, affective ToM and
emotion recognition have been shown to activate overlapping
brain regions, namely the inferior frontal gyrus, the superior
temporal sulcus, the temporal pole and the amygdala (Mier et al.,
2010) Despite this, ToM is an area of research that has received
relatively little attention in HD. Changes in empathy have been
found in patients with manifest HD demonstrated by their im-
paired interpretation of humorous cartoons and story vignettes
(Snowden et al., 2003). Further abnormalities have been shown in
similar populations of HD patients on ToM tasks such as the
“Reading the Mind in the Eyes Task” (RMET) and the faux pas task
(Eddy et al., 2012, 2014; Allain et al., 2011) with deﬁcits in ToM
found to relate to executive functioning (Allain et al., 2011; Brune
et al., 2011) however, to our knowledge however, ToM has not
been studied in PMGC's. In this study the RMET was used as a
surrogate clinical measure of amygdala function on the basis of
previous studies (Adolphs et al., 2002), rather than to interrogate
ToM in HD.
In the current study we used an implicit emotional processing
task to look for differences in neural activation between PMGC's
and healthy controls when viewing grey scale pictures of angry
and neutral faces. Unlike previous studies, the pictures of faces
were contrasted with pictures of buildings and participants were
asked to respond indicating whether they saw a face or a house on
the screen. Houses were used as a contrast in this task to increase
the power to functionally detect differences in BOLD response
during the processing of angry but not neutral faces and not to
mask the effect of brain regions which have been previously
shown to be activated, non-discriminately by all facial emotions
(Fitzgerald et al., 2006).
Connectivity analysis of the results indicated that abnormalities
in the way that activity in the amygdala covaries with other brain
regions during emotional processing may be an early disease re-
lated marker in PMGC's. To identify whether this could be mea-
sured clinically, a validated theory of mind test (ToM) which has
previously been shown to impaired in patients with lesions to the
amygdala (Stone et al., 2003): the Reading the Mind in the Eyes
Test (RMET) (Baron-Cohen et al., 2001), was used in a population
of PMGC's (11 of whom also underwent the fMRI study) and ex-
tended to a population of manifest patient from all different stages
of the disease.
The combination of the two experiments provides a compre-
hensive assessment of amygdala related emotional processing in
HD from the earliest pre-manifest stage of the disease through to
advanced HD. On the basis of the existing literature we initially
predicted that PMGC's would have decreased activation in and
connectivity in a wide network of brain regions compared to
Table 2
Clinical characteristics of the PMGC's. Mean (standard deviation) is tabulated unless
otherwise stated. Between group comparisons using one-way Analysis of Variance.
PMGC PMGC Control Control far p Value
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ing the imaging study we then went on to hypothesise that ab-
normalities in ToM performance would increase progressively at
more advanced stages of the disease in HD.close far close
N 10 10 12 11
Gender (F:M) 3:7 5:5 5:7 8:3
Age (years) 49.6
(11.4)
41.5 (9.8) 45.0 (13.6) 38.7 (11.1) 0.17 (ns)
CAG repeat length 42.1 (2.5) 40.3 (1.3) n/a n/a 0.1 (ns)
Estimated time to
onset
10.5 (2.9) 23.8
(6.9)
n/a n/a 0.001
Disease burden
score
293.4
(58.6)
176.4
(37.0)
n/a n/a 0.001
UHDRS 3.3 (2.5) 0.4 (1.0) n/a n/a 0.003
Diagnostic con-
ﬁdence score
1.0 (1.1) 0.2 (0.4) n/a n/a 0.039
Abbreviations – CAG: cytosine–adenine–guanine, UHDRS: Uniﬁed Huntington's2. Methods, materials and results
2.1. Participants
All participants were recruited from the multidisciplinary
Huntington's disease service clinic at the John Van Geest Centre
for Brain Repair, UK. Control subjects were recruited through links
with the clinic. Approval for this study was granted by the Local
Regional Ethics Committee and Addenbrooke's hospital R&D de-
partment. Informed consent was taken from participants.
Two cohorts of participants were recruited:
Disease Rating Scale,1.Tab
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TFA20 Pre-manifest HD gene carriers (PMGC) (10 males, average
age¼45.8 years S.D¼11.16) and 23 controls (10 males, average
age¼42.1 years S.D.¼12.04) underwent functional imaging.2. 29 PMGC (14 males, average age¼43.5 years S.D¼9.5) 11 of
whom were also scanned (5 males, average age¼47.7 years S.
D¼13.2), 50 manifest patients (27 males, average age¼54.4 S.
D¼12.1) and a further 26 different healthy controls (14 male,
average age¼59.0 S.D¼11.7) were tested on the RMET.
Participant demographics are detailed in Tables 1 (cohort 1)
and 2 (cohort 2).
2.2. Study 1: methods
2.2.1. fMRI task
To test neural activation in response to pictures of angry faces,
participants underwent functional MRI scanning. Stimuli were
visible via an angled mirror positioned above their eyes reﬂecting
images projected onto a screen at the end of the scanner bor.
Responses were made using the ﬁrst 2 buttons on a 4 button re-
sponse box held in the participant's right hand. Participants were
instructed to press button 1 to identify a house and button 2 to
identify a face.
The “face” stimuli had either an angry or a neutral expression,
although participants were not informed of the difference in
emotional expressions and were not required to respond differ-
ently to faces of different emotions. The “face” photographs werele 1
ographic and clinical characteristics of all participants who completed Reading the
ween group comparisons were made using one way Analysis of Variance where app
RMET
Control PMGC Early
26 29 12
ge (yrs) 59.0nn (11.7) 43.5 (9.5) 54.1nn (11.5)
ender (f:m) 12:14 15:14 3:9
ART 116.9 (5.1) 111.9 (7.1) 115.3 (7.9)
MSE 29.0 (1.3) 29.2 (1.6) 28.3 (1.2)
DI 4.6 (3.8) 7.8 (7.9) 6.9 (6.6)
AS ND 40.6 (14.00) 30.2 (12.5)
HDRS N/A 1.3 (2.2) 16.4nn (8.0)
FA N/A 25.1 (0.4) 26.3 (1.2)
a are mean (standard deviation).
ET & scanning¼pre-manifest HD gene carriers who completed both studies.
reviations – BDI: Beck Depression Inventory, FAS: verbal ﬂuency, MMSE: Minimenta
: Total Functional Assessment, UHDRS: Uniﬁed Huntington's Disease Rating Scale,
n Signiﬁcantly different from controls, po0.05.
nn Signiﬁcantly different from pre-HD, po0.05.selected from the NimStim Face Stimulus Set (www.macbrain.org)
and the Karolinska directed emotional faces (KDEF); they were
chosen on the basis of independent emotional ratings. Participants
were presented with each expression 32 times giving a total of 64
pictures of faces from 33 separate actors. The gender and identify
of faces was fully randomised. 320 pictorial stimuli were presented
in total with the remaining 256 pictures made up of 20 different
houses. The two performance effects of interest were infrequent
(face) vs. frequent (house) stimuli and angry vs. neutral face
stimuli.
Pictures were presented in a predeﬁned pseudo-randomised
order followed by a low contrast central cross. Each stimulus was
presented for 750 ms, with an inter-trial interval of 750 ms to
encourage participants to respond quickly and instinctively to the
pictures and to reduce awareness of the overt emotional content of
the face stimulus. The total experiment lasted for 9 min 20 s.
2.2.2. fMRI data acquisition
Patients were scanned at the MRC Cognition and Brain Sciences
Unit, Cambridge, using a 3T Siemens TIM Trio MRI scanner. During
the task 290 T2-weighted echo-planar images depicting BOLD
signal were acquired, the ﬁrst 10 of which were discarded to avoid
T1-equilibrium effects. Each image consisted of 32 slices of 3 mm
thickness with a 1 mm interslice gap and an in-plane resolution of
33 mm2. The repetition time (TR) was 2 s with an echo time (TE)Eyes in the Mind Task. Mean (standard deviation) reported unless otherwise stated.
ropriate.
Combined
Moderate Late PMCG p Value
18 20 11
52.8nn (14.4) 56.1nn (10.2) 47.7 (13.2) 0.001
9:9 7:13 6:5
112.4 (10.6) 109.5n (5.8) 111.5 (9.2) 0.34 ns
27.5 (1.9) nn 25.9n (3.7) nn 29.9 (0.4) 0.001
11.4 (9.3) 10.9 (5.4) 6.5 (6.0) 0.40 ns
30.2 (15.1) 18.8 (11.3)nn 44.4 (18.8) 0.001
21.8nn (10.6) 37.5nn (14.0) 1.5 (3.0) 0.001
29.4nn (1.9) 35.6nn (2.3) 25.0 (0.0) 0.001
l State Exam, N/A: not applicable, NART: National Adult Reading Test, ND: not done,
S.L. Mason et al. / Neuropsychologia 70 (2015) 80–89 83of 30 s. Slices were angled away from the orbits to avoid signal
dropout due to magnetic susceptibility inhomogeneity. Stimuli
were presented on a screen with a resolution of 1024768 pixels
which was visualised using a mirror positioned within the scanner
at a viewing distance of 90 mm.
2.2.3. Data analysis
2.2.3.1. Behavioural data. Behavioural performance was evaluated
using two outcome measures: accuracy (percentage of pictures
correctly classiﬁed) and mean latency to response for both angry
and neutral faces. No accuracy measures were taken for the
“house” stimuli. Multivariate analysis of variance (MANOVA) was
used to compare performance between gene carriers and controls
and a repeated measures analysis of variance (rm-ANOVA) was
used to compare performance between emotional conditions.
2.2.3.2. Imaging data preprocessing. MRI data were processed using
SPM8 (www.ﬁl.ion.ucl.ac.uk/spm). Functional MRI data were con-
verted from DICOM to NIFTII images, spatially realigned to the ﬁrst
image, and corrected for acquisition delay with references to the
middle slice. There was no exclusion of subjects. All subjects that
had ﬁnished the EGNG task were included in the analysis. To de-
termine whether the preHD group had greater movements during
image acquisition than controls', a measure of displacement was
obtained for each subject using the motion correction parameters
from SPM realignment function. We took the translation and ro-
tation measurements in x, y, and z co-ordinates between each
volume and then calculated the root mean square of the three
translations and the three rotations. We then summed the trans-
lation and rotation measures across all the volumes to give indexes
of the total displacement for each subject. There was no signiﬁcant
effect of group (pre-HD or control) on total amount of translation
(F(1,42)¼3.24, p¼0.08) or rotation (F(1,42)¼1.64, p¼0.21) during
scanning. The mean fMRI and MP-RAGE images were coregistered
using mutual information, and the MP-RAGE image was seg-
mented and normalised to the Montreal Neurological Institute
(MNI) T1 template by linear and non-linear deformations. The
normalisation parameters were applied to all spatiotemporally
realigned functional images, and normalised images were re-
sampled to 222 mm3 before smoothing with an isotropic
Gaussian kernel with full-width half-maximum of 8 mm.
2.2.3.3. fMRI data analysis. A ﬁrst level general linear model (GLM)
included three epoch regressors (angry faces, neutral faces, and
houses) for trials with correct responses. Additional regressors
representing trials with incorrect or omitted responses and six
rigid-body motion correction parameters were included as nui-
sance covariates. Regressors were convolved with a canonical he-
modynamic response function, and the data were high-pass ﬁl-
tered with a frequency cutoff at 128 s.
To assess brain activity associated with angry processing, ﬁrst-
level contrast images were generated for angry vs. neutral faces
and these were entered into a second-level analysis to test for
averaged effects across participants and group effects between
PMGC and controls.
2.2.3.4. Psychophysiological interactions for brain connectivity ana-
lysis. A PPI analysis was performed to examine the functional
connectivity between the amygdala and other potential brain re-
gions during emotional processing (Passamonti et al., 2008; Fris-
ton et al., 1997). The PPI analysis tested how physiological con-
nectivity between a source region at amygdala and the rest of the
brain varied with the psychological context (i.e., angry vs. neutral
faces).
Our primary interest is the angry vs. neutral faces comparison
in the connectivity analysis. A second contrast, angry faces vs.houses was used to increase the power to functionally detect the
amygdala, because neutral faces have also been shown to active
the amygdala (Fitzgerald et al., 2006; Wright and Liu, 2006). Two
further contrasts (faces vs. houses and houses vs. faces) were
conducted as a sanity check, ensuring that our task activates the
functionally speciﬁc regions. Note that previous studies showed
that the comparison between angry faces to houses increased the
power to detect the amygdala (Passamonti et al., 2008). Although
the task has been shown to active the amygdala in this and pre-
vious studies, the cluster extends beyond amygdala (see Fig. S1,
supplementary data). Therefore it is not straightforward to use the
fMRI results as a localizer. Here we used the same approach as in
our previous study (Passamonti et al., 2008) where the contrast
angry faces vs. houses was used to ﬁnd the peak voxel in the
amygdala (24, 4, 16), and deﬁned a 10-mm sphere around
this peak coordinate. Our previous study showed that this ap-
proach gave similar result as deﬁning a subject-speciﬁc ROIs
(Passamonti et al., 2008).
For each participant, we computed the ﬁrst eigenvariate of the
BOLD time courses from all voxels in the left amygdala ROI and
derived the “neural signal” of the source region by deconvolving
the hemodynamic response function. The psychophysiological in-
teraction regressor was calculated as the product of the decon-
volved time course and a vector coding for the psychological
variable (1 for angry faces, 1 for neutral faces). Participant spe-
ciﬁc PPI models included the psychological (angry faces vs. neutral
faces), physiological (left amygdala signal), and psychophysiolo-
gical variables and were re-convolved by the canonical hemody-
namic response function. Six motion correction parameters were
included as nuisance covariates. First-level contrast images were
generated for PPIs and were entered into second level GLM ana-
lysis for contrasts of interest.
2.3. Study 1: results
2.3.1. Demographics
Patient demographics and clinical characteristics are shown in
detail in Table 2. PMCG's were well matched with controls for age.
As predicted the PMGC “close” and “far” groups differed from each
other in terms of estimated time to onset (F(1,19)¼26.68,
po0.0001), disease burden score (F(1,19)¼17.02, po0.001) and
UHDRS score (F(1,19)¼6.25, po0.05).
2.3.2. Behavioural results
Patients responded to pictures of faces as quickly (F(3,47)¼
0.925, p¼0.44) and accurately (F(3,47)¼2.08, p¼0.13) as controls.
The angry/neutral contrast was an implicit feature of the task
design, however there was no signiﬁcant effect of emotion on
accuracy (F(3,40)¼1.803, p¼0.162) or latency (F(3,40)¼0.783,
p¼0.511).
2.3.3. Connectivity analysis
Details on the brain regions activated during the task have been
reported in supplementary Fig. S1. we deﬁned the left amygdala as
the seed region (10 mM sphere centred at 24, 4, 16) from an
“angry faces” minus “houses” contrast for PPI analysis (supple-
mentary Fig. S2, also see PPI connectivity analysis in Section 2).
neural activity in the seed region was found to covary positively
with the bilateral fusiform facial area (FFA) (left: 32, 78, 8;
right: 38, 78, 4) and caudal anterior cingulate (left: 10, 20,
36; right: 16, 8, 34) across all participants during exposure to
angry faces (Fig. 1A). Differences were detected in the extent of PPI
activity between the left amygdala and the right FFA (30, 70,
10) (Fig. 1B) with PMGC exhibiting reduced connectivity com-
pared to controls, corrected for multiple comparison at the cluster
level (FDR corrected po0.05).
Fig. 1. PPI GLM statistical parametrical maps. (A) Positive PPI effects originating from the amygdala during exposure to ‘angry faces’ relative to ‘neutral faces’ for all
participants at a liberal threshold (po0.001 uncorrected, cluster size 50 voxels or more). (B) Decreased PPI connectivity in PMGC's during exposure to ‘angry faces’ relative to
‘neutral faces’ (po0.05, cluster level corrected).
S.L. Mason et al. / Neuropsychologia 70 (2015) 80–8984PPI connectivity between the left amygdala and the right FFA
correlated signiﬁcantly with estimated years to disease onset
(r¼0.45, po0.05) but not disease burden score (r¼0.28,Fig. 2. Correlation between PPI connectivity originating from the amygdala to the right
score in PMGC's. Participants have be divided into “close” to and “far” from onset group
visually represent those gene carriers who have received (conﬁrmed) or are anticipated
show the standard errors across all healthy controls. The regression line (solid) and thep¼0.24) (Fig. 2). Change in PPI connectivity scores did not corre-
late signiﬁcantly with age for controls (r¼0.04, p¼0.86) but
there was a signiﬁcant relationship in PMGC (r¼0.54, po0.01).fusiform facial area and (A) estimated years to disease onset and (B) disease burden
s and further subdivided into pre-manifest, intermediate and conﬁrmed groups to
to imminently receive a diagnosis of HD (intermediate) since scanning. Error bars
95% conﬁdence intervals (dashed) are shown.
Fig. 3. Behavioural performance on the Reading the Mind in the Eyes task stratiﬁed
by disease stage for all HD participants. n indicates a signiﬁcant difference com-
pared to controls at the p¼0.05 level.
Fig. 4. Performance on the Reading the Mind in the Eyes Tasks correlated with total
functional assessment score from the UHDRS.
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2.4.1. Background assessments
Pre-morbid verbal IQ was estimated using the National Adult
Reading Test (NART) (Nelson, 1982). Depressive symptomatology
was evaluated using the Beck Depression Inventory revised (BDI)
(Beck et al., 1961), global cognitive function was measured using
the Mini Mental State Exam (MMSE) (Folstein et al., 1975) and
verbal ﬂuency was measured to provide a small insight into ex-
ecutive dysfunction (Henry et al., 2005).
Motor impairment and daily functioning were assessed by an
experienced neurologist using the UHDRS (Huntington Study
Group, 1996) motor, total functional assessment, total functional
capacity and independence score subscales for all HD gene car-
riers. Gene carriers with a UHDRS score of r5 were classiﬁed as
PMCG's. Manifest patients were staged according to previously
published criteria based on the Total Functional Capacity (TFC)
score: scores of between 11 and 13 were classiﬁed as early disease,
between 7 and 10 as moderate disease and scores of 6 and less as
late disease (Begeti et al., 2013).
2.4.2. Social cognition task
The Reading the Mind in the Eyes Task (RMET) (Baron-Cohen
et al., 2001) is a measure of affective ToM. Participants are pre-
sented with a picture showing the eye region in isolation from the
rest of the face. The participant is required to say which of
4 emotional/mental state words positioned around the picture
best captures the thoughts or feelings portrayed in the eyes. Total
number of correct responses was recorded.
2.4.3. Data analysis
Levene's test for Equality of Error Variances conﬁrmed homo-
geneity of variance therefore between-group differences were
examined using analysis of variance (ANOVA) with post-hoc
comparison by t-tests with Bonferroni correction for multiple
comparisons. However, when tested at the whole group level
using a Shapiro–Wilk test (p¼0.18), performance on the RMET was
not normally distributed therefore performance was correlated
with clinical markers of disease progression (UHDRS motor score
and disease burden score) and daily functioning (TFA) using a
Spearman's Rho non-parametric correlation. Furthermore, the
data was normalised and linear regression analyses were used to
quantify the strength of the relationship between RMET and
UHDRS, DBS, and NART. The following variables were not included
because of their relationship with other variables in the regression
analyses: age because it was strongly associated with DBS, verbal
ﬂuency because it was associated with NART and BDI because it
was associated with UHDRS. All analyses were performed on
Predictive Analytic SoftWare (PASW) Statistics, version 21.
2.5. Study 2: results
2.5.1. Demographics
Participant demographics and clinical characteristics are shown
in detail in Table 1. In general the manifest patients were well
matched with controls for age, NART and BDI however, PMGC were
signiﬁcantly younger than controls (F(5,97)¼5.50, po0.001) and
late stage patients had a signiﬁcantly lower NART than controls (F
(5,96)¼2.57, po0.05). As anticipated, manifest patients were
found to have a higher UHDRS (F(4,74)¼65.56, po0.001), lower
total functional assessment (FA) scores (F(4,74)¼156.5, po0.001),
lower verbal ﬂuency score than PMGC's (F(3,72)¼10.00, po0.01)
and lower MMSE scores (F(5,92)¼12.37, po0.001) compared to
PMGC's. It should also be noted that gender distribution in the
early HD group was uneven with more men than women and may
therefore effect the analysis.2.5.2. Manifest HD
Total number of correct responses on the RMET task deterio-
rated signiﬁcantly with disease stage (F(7,65)¼9.377, po0.001)
(Fig. 3). Post hoc investigation revealed that PMCG's were the only
group not to differ from controls (p¼1.0).
Performance on the RMET task correlated with motor impair-
ment (r2¼0.71, po0.001), disease burden score (r2¼ 0.69,
po0.001) and the UHDRS functional assessment (FA) score
(r2¼0.60, po0.01), Fig. 4. Linear regression analyses identiﬁed
that RMET performance related to UHDRS (t¼4.0, po0.001),
NART (t¼3.64, po0.001) and DBS (t¼2.17, po0.05).
2.5.3. Pre-manifest HD gene carriers
Performance on the RMET task correlated with the number of
estimated years to disease onset (r2¼0.52, po0.005) and disease
burden score (r2¼0.41, po0.05) (Fig. 5) in PMGC's with perfor-
mance deteriorating as the time to disease onset shortened. How-
ever, on all other measures PMGC's were equivalent to controls.
2.5.4. PPI connectivity and performance on the RMET
Performance on the RMET and change in PPI connectivity be-
tween the left amydgala and rFFA was not signiﬁcantly correlated
Fig. 5. Correlation between performance on the Reading the Mind in the Eyes task
and (A) the estimated number of years to disease onset and (B) the disease burden
score in PMGC's.
Fig. 6. Correlation between PPI connectivity between the amygdala and the right
fusiform facial area and performance on the Reading the Mind in the Eyes Task in
PMGC's. The regression line (solid) and the 95% conﬁdence intervals (dashed) are
shown.
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2 PMGC's who completed the two studies greater than 1 year apart
was removed, performance on the RMET signiﬁcantly correlated
with change in PPI connectivity (r¼0.77, po0.05). Although cau-
tion should be expressed when interpreting these data due to the
small sample size they provide relevant exploratory insights.3. Discussion
The combined results of these studies suggest that the amyg-
dala is affected early in the course of HD; even from the late pre-
manifest stage. Speciﬁcally, connectivity between the left amyg-
dala and the right FFA reduces in line with estimated time to
disease onset during emotional processing; the magnitude of this
effect relates to proximity to disease onset. Additionally, perfor-
mance on the RMET, a task known to activate the amygdala (Stone
et al., 2003), in PMGC's also correlated with estimated proximity to
disease onset and deteriorated further with every cross-sectional
disease stage. Finally, PPI connectivity and RMET performance
correlated highly in the small subgroup of PMGC's who completed
both studies within a 1 year window.To our knowledge this is the ﬁrst study to look at the inﬂuence
of disease stage on social cognition performance and the ﬁrst to
report a relationship with predicted time to disease onset in
PMGC's. Consistent with the work of others, the RMET was found
to be a sensitive tool capable of detecting deﬁcits in social cogni-
tion in HD (Eddy et al., 2012; Allain et al., 2011). In addition
however, we were able to demonstrate that performance on the
RMET was inﬂuenced by the length of exposure to the pathological
effects of the CAG expansion (DBS), motor symptomatology
(UHDRS) and cognitive reserve (NART). All of which support the
use of the RMET as a clinical outcome measure in HD.
Successful completion of the RMET is heavily reliant upon ac-
tivation of the amygdala (Stone et al., 2003); a region that has been
implicated in face (Rolls, 1992) and facial emotion processing
(Harris et al., 2014), speciﬁcally during recognition of fearful faces
(Adolphs et al., 1994). Analysis of functional MRI data collected in
this study found reduced functional connectivity between the left
amygdala and rFFA in PMGC's compared to healthy controls when
exposed to pictures of angry faces. Reduced functional con-
nectivity has previously been shown in PMGC's during tasks of
working memory (Georgiou-Karistianis et al., 2013; Poudel et al.,
2015), planning (Unschuld et al., 2013) and motor performance
(Unschuld et al., 2012). However, to the best of our knowledge, this
is the ﬁrst study to look at functional connectivity during emo-
tional processing in such a group. Of relevance to this is a recent
meta-analysis looking at regions of degeneration in PMGC's which
identiﬁed the amygdala as a region commonly reported as vul-
nerable to HD neuropathology (Dogan et al., 2013). In addition the
amygdala has also been linked to subjective fear responses in
manifest HD (Eddy et al., 2011) and the recognition of emotions
such as disgust and happiness (Hayes et al., 2007; Kipps et al.,
2007) in PMGC's; while in rodent models of HD neuropathology in
the amygdala has been shown to be associated with social and
emotional memory (Ciamei and Morton, 2008; Faure et al., 2013),
and motivational processes (Faure et al., 2011). Consistent with
this literature the current study provides evidence of amygdala
dysfunction in HD beginning prior to the onset of overt clinical
features.
Both tasks used in this study involve some element of social
cognition and are both reliant upon amygdala function thereby
implicating the amygdala in the process of interpreting social
meaning (Adolphs et al., 2002, 1994) rather than in the
S.L. Mason et al. / Neuropsychologia 70 (2015) 80–89 87identiﬁcation of speciﬁc emotions. Additional support for this
theory comes from emerging evidence from the wider literature
that suggests that the amygdala is responsible for detecting per-
ceptual salience and biological relevance in facial emotions
(Adolphs, 2008; Sander et al., 2005). Furthermore, a recent study
of neurosurgical patients with chronically implanted depth elec-
trodes in the amygdalae demonstrated that there are neurons in
this structure that code speciﬁcally for both fearful and happy
faces (Wang et al., 2014).
The complementary evidence from both the RMET and fMRI
studies presented here, especially the involvement of the amyg-
dala in both tasks support the rationale that both social cognition
and emotional processing in HD share a common neural pathway.
Moreover, it has previously been reported that impairments in the
recognition of fear following amygdala damage are a result of an
inability to ﬁxate on the eye region of the face (Adolphs et al.,
2005), therefore we propose that the wider emotional processing/
social cognition problems seen in HD are caused by a similar im-
pairment: a shift in attention away from the eye region of the face
during emotional processing, mediated by neuronal dysfunction in
the amygdala. Further work is needed to directly test this theory
and the RMET may be a useful and reliable way of measuring the
functional integrity of this pathway. It may also be useful, in
combination with measures such as statistical estimates of disease
burden and the presence of subtle motor signs, as a way of iden-
tifying PMGC's at risk of phenoconverting.
It is noteworthy that the PPI connectivity correlated with pre-
dicted time to disease onset but not DBS which initially appears
surprising however, may be explained by the differences between
the two models. Predicted time to disease onset was calculated
using the Langbehn et al. (2004) survival analysis equation in this
study. This model deals exclusively with the pre-manifest stage of
HD and estimates the age at which a gene carrier will meet the
criteria for clinical diagnosis. Age at diagnosis has been shown to
be highly inﬂuenced by the CAG length (Langbehn et al., 2010).
However, CAG length has less of an effect on the rate of disease
progression in manifest disease. Therefore, when looking at the
relationship between RMET and clinical measures of HD, the DBS
(Penney et al., 1997) was used as a continuous variable that could
be applied to all gene carriers (both PMGC's and manifest pa-
tients). The DBS is a linear equation that places less emphasis on
the CAG repeat size and more on the age of the participant (or the
time of exposure to the effects of the expansion) which provides
an estimate of HD pathology. The DBS has been shown to be a
good predictor of striatal pathology in post-mortem tissue (Penney
et al., 1997). Based upon this, reduced PPI connectivity between
the amygdala and FFA could be a useful outcome measure for
monitoring proximity to disease onset but not disease progression.
Therefore it may be useful future disease modifying trials in
PMGC's. Conversely, the RMET is a useful tool by which to assess
disease onset and progression.
The ﬁndings of this study may be useful when trying to un-
derstand the cause of the deterioration seen in daily functioning in
the early stages of HD (Williams et al., 2007) although further
work is needed to establish a link between the two. However, it is
difﬁcult to ascertain the impact that such a change has on the
quality of life (QoL) of PMGC's and their families as the scales and
assessments that are currently available to measure QoL, while
useful in manifest disease, are not sensitive enough to detect
change in the pre-manifest stage. Based upon the ﬁndings of this
study this is an area that warrants further investigation.
There are clear limitations to the work presented here which
need to be acknowledged. Due to the evolution of this project over
a number of years, only a small number of PMGC's completed both
the functional imaging and the RMET within a 1 year window. This
reduced our power to detect between group differences, althougha signiﬁcant relationship was identiﬁed, but also potentially limits
the generalisability of the data to a wider HD population. Further
work is needed to conﬁrm the link between amygdala connectivity
and RMET in a larger cohort of PMGC's taking these points into
consideration. Furthermore, emotion recognition was not tested in
the PMGC's therefore we do not know whether or how reduced
PPI connectivity relates to clinically measureable abnormalities in
emotional processing. Also, given the potential utility of the RMET
for both clinical and research endpoints, a systematic evaluation of
the factors inﬂuencing ToM and emotional processing in HD is
warranted. For example, executive function (Henry et al., 2006),
mood (Fertuck et al., 2009) and age (Pardini and Nichelli, 2009)
have all been shown to effect performance in other disorders,
however, due to time restraints and the complexity of studying
advanced HD patients these were not adequately considered in the
current study but should be considered in future work. Further-
more, it should be noted that the PPI analyses were completed
using a more liberal threshold for comparison thanwas used in the
whole brain imaging analyses. This was because the effect seen
following the PPI analysis was not of sufﬁcient strength to with-
stand correction for multiple comparisons; mostly likely due to the
number of participants studied. Therefore these results need to be
studied further.
In summary, this work provides evidence that the amygdala
and its connections are involved in the loss of high order emo-
tional processing in HD. Both loss of effective connectivity be-
tween the amygdala and the FFA and performance on the social
cognition task, correlated with time to disease onset and may be
useful in identifying PMGC's who are at immediate risk of devel-
oping overt disease. In addition, social cognition performance
continues to be a useful marker of emotional processing cap-
abilities and social cognition throughout advancing disease mak-
ing it a promising task for monitoring the complex cognitive
changes associated with disease progression.Conﬂict of interest
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